Literature DB >> 31771762

Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.

Diana Saleiro1, Leonidas C Platanias2.   

Abstract

The interferons (IFNs) are cytokines with important antineoplastic and immune modulatory effects. These cytokines have been conserved through evolution as important elements of the immune surveillance against cancer. Despite this, defining their precise and specific roles in the generation of antitumor responses remains challenging. Emerging evidence suggests the existence of previously unknown roles for IFNs in the control of the immune response against cancer that may redefine our understanding on how these cytokines function. Beyond the engagement of classical JAK-STAT signaling pathways that promote transcription and expression of gene products, the IFNs engage multiple other signaling cascades to generate products that mediate biological responses and outcomes. There is recent emerging evidence indicating that IFNs control the expression of both traditional immune checkpoints like the PD-L1/PD1 axis, but also less well understood "intracellular" immune checkpoints whose targeting may define new approaches for the treatment of malignancies. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer; Immune checkpoint; Immune response; Interferon; Non-canonical pathways; Signaling

Mesh:

Substances:

Year:  2019        PMID: 31771762      PMCID: PMC8177745          DOI: 10.1016/j.smim.2019.101299

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  135 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 2.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 4.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  Schlafen 12 mediates the effects of butyrate and repetitive mechanical deformation on intestinal epithelial differentiation in human Caco-2 intestinal epithelial cells.

Authors:  Lakshmi S Chaturvedi; Qinggang Wang; Shyam K More; Emilie E Vomhof-DeKrey; Marc D Basson
Journal:  Hum Cell       Date:  2019-03-14       Impact factor: 4.174

6.  Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling.

Authors:  Surinder Kaur; Antonella Sassano; Ajith M Joseph; Beata Majchrzak-Kita; Elizabeth A Eklund; Amit Verma; Saskia M Brachmann; Eleanor N Fish; Leonidas C Platanias
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

7.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors:  D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

8.  SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing.

Authors:  Riccardo Mezzadra; Marjolein de Bruijn; Lucas T Jae; Raquel Gomez-Eerland; Anja Duursma; Ferenc A Scheeren; Thijn R Brummelkamp; Ton N Schumacher
Journal:  PLoS One       Date:  2019-02-12       Impact factor: 3.240

9.  Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors.

Authors:  I Gresser; F Belardelli; C Maury; M T Maunoury; M G Tovey
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

10.  SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects.

Authors:  Sarah J Fletcher; Ben Johnson; Gillian C Lowe; Danai Bem; Sian Drake; Marie Lordkipanidzé; Isabel Sánchez Guiú; Ban Dawood; José Rivera; Michael A Simpson; Martina E Daly; Jayashree Motwani; Peter W Collins; Steve P Watson; Neil V Morgan
Journal:  J Clin Invest       Date:  2015-08-17       Impact factor: 19.456

View more
  12 in total

1.  EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.

Authors:  Antonio Marzio; Emma Kurz; Jennifer M Sahni; Giuseppe Di Feo; Joseph Puccini; Shaowen Jiang; Carolina Alcantara Hirsch; Arnaldo A Arbini; Warren L Wu; Harvey I Pass; Dafna Bar-Sagi; Thales Papagiannakopoulos; Michele Pagano
Journal:  Cell       Date:  2021-12-27       Impact factor: 41.582

2.  [ELF4 promotes proliferation and inhibits apoptosis of human insulinoma cells by activating Akt signaling].

Authors:  G Wei; L Wang; X Wan; Y Tan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-08-31

3.  Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts.

Authors:  Hendrik J Kuiken; Sabin Dhakal; Laura M Selfors; Chandler M Friend; Tian Zhang; Maurizio Callari; Ron C J Schackmann; G Kenneth Gray; Jett Crowdis; Hyo-Eun C Bhang; Timour Baslan; Frank Stegmeier; Steven P Gygi; Carlos Caldas; Joan S Brugge
Journal:  Oncogene       Date:  2021-10-26       Impact factor: 9.867

Review 4.  Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways.

Authors:  Candice Mazewski; Ricardo E Perez; Eleanor N Fish; Leonidas C Platanias
Journal:  Front Immunol       Date:  2020-11-23       Impact factor: 7.561

5.  Nanoparticle encapsulated CQ/TAM combination harmonizes with MSCs in arresting progression of severity in AP mice through iNOS (IDO) signaling.

Authors:  Huimin Liu; Simeng Liu; Xiaoshuang Song; Ailing Jiang; Yu Zou; Yuchuan Deng; Chao Yue; Zhenlu Li; Dujiang Yang; Chengli Yang; Dan Sun; Fan Yang; Mao Li; Kun Jiang; Huimin Lu; Weiming Hu; Yu Zheng
Journal:  Mater Today Bio       Date:  2022-02-26

Review 6.  Type I interferon-mediated tumor immunity and its role in immunotherapy.

Authors:  Renren Yu; Bo Zhu; Degao Chen
Journal:  Cell Mol Life Sci       Date:  2022-03-16       Impact factor: 9.207

7.  Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.

Authors:  Diana Saleiro; Jeremy Q Wen; Ewa M Kosciuczuk; Frank Eckerdt; Elspeth M Beauchamp; Chidera V Oku; Gavin T Blyth; Mariafausta Fischietti; Liliana Ilut; Marco Colamonici; William Palivos; Paula A Atsaves; Dean Tan; Masha Kocherginsky; Rona Singer Weinberg; Eleanor N Fish; John D Crispino; Ronald Hoffman; Leonidas C Platanias
Journal:  Nat Commun       Date:  2022-04-01       Impact factor: 17.694

8.  Regulation of IFNα-induced expression of the short ACE2 isoform by ULK1.

Authors:  Ricardo E Perez; Diana Saleiro; Liliana Ilut; Gary E Schiltz; Frank Eckerdt; Eleanor N Fish; Leonidas C Platanias
Journal:  Mol Immunol       Date:  2022-04-27       Impact factor: 4.174

Review 9.  Self-adjuvanting cancer nanovaccines.

Authors:  Zhiyun Liao; Jing Huang; Pui-Chi Lo; Jonathan F Lovell; Honglin Jin; Kunyu Yang
Journal:  J Nanobiotechnology       Date:  2022-07-26       Impact factor: 9.429

Review 10.  Type I and II Interferons in the Anti-Tumor Immune Response.

Authors:  Sarah E Fenton; Diana Saleiro; Leonidas C Platanias
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.